0001593968-23-000583.txt : 20230405
0001593968-23-000583.hdr.sgml : 20230405
20230405184325
ACCESSION NUMBER: 0001593968-23-000583
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230401
FILED AS OF DATE: 20230405
DATE AS OF CHANGE: 20230405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Lillian
CENTRAL INDEX KEY: 0001971448
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 23803875
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_01.xml
PRIMARY DOCUMENT
X0407
4
2023-04-01
0001737287
Allogene Therapeutics, Inc.
ALLO
0001971448
Smith Lillian
210 EAST GRAND AVE
SOUTH SAN FRANCISCO
CA
94080
true
VP, Corporate Counsel
false
Common Stock
2023-04-01
2023-04-03
4
A
false
56545
0
A
140390
D
Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated on March 22nd, 2026 if such threshold has not been met, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after March 22nd, 2028 if such approval has not occurred.
/s/Lillian Smith
2023-04-05